It has been well established that bacterial lipopolysaccharides (LPSs) exert a multiplicity of biological influences in the host, including stimulation of defense systems to infectious diseases and tumors. Numerous investigators have shown that relatively small amounts of LPS, injected 24 h prior to challenge infection, can protect mice from succumbing to lethal infection (for a review, see reference 14) . The mechanisms by which LPS exerts its beneficial effects in the host are complex and incompletely understood, but they are believed to be mediated by the action of cytokines liberated by host cells upon interaction with LPS (18) . One of the earliest cytokines produced in response to LPS is tumor necrosis factor (TNF), or cachectin. Studies in vivo have shown that the maximum concentration of TNF in serum is attained within 2 h following a single intravenous injection of LPS into LPS-responsive mice (9) and human volunteers (11) . The monocyte or macrophage appears to be the principal cell type responsible for the production and release of TNF (10, 15) .
There is ample evidence implicating TNF as a key mediator in the deleterious effects of LPS, i.e., endotoxin shock (for a review, see reference 3). However, there are an increasing number of studies indicating that this monokine is capable of influencing numerous other biological pathways that may ultimately be important in enhancing resistance to infectious disease. Included among the immunomodulatory effects described for TNF are induced alterations in leukocyte recruitment and trafficking in vivo (12, 20) , up-regulation of interleukin-2 receptors and cytolytic activity of lymphoid cells (17) and complement receptors on neutrophils (1), priming of neutrophils for oxidative burst activity (2), activation of macrophages in vitro and in vivo (4, 16, 19) , priming of macrophages and neutrophils for enhanced killing of intracellular parasites (5), and stimulation of proliferation and differentiation in B cells (8) , T cells (23) , and hematopoietic progenitor cells (22) . There are several recent studies which more closely link TNF with increased resistance to infections. Injection of TNF 1 day prior to experimental peritonitis in mice caused by cecal ligation and puncture provided significant protection from mortality. There was no observed protection when TNF was administered immediately prior to surgery (21) .
Since it is known that the production of TNF is an early host response to LPS challenge, it was of interest to determine whether TNF could replace LPS in providing pro-* Corresponding author. tection against Listeria infection. Recombinant human TNF alpha (rHuTNF-a) was produced in Escherichia coli and purified by high-pressure liquid chromatography (HPLC)-ion-exchange chromatography, HPLC-hydrophobic interaction chromatography, and HPLC-gel filtration. The purified rHuTNF-ot gave a single protein band on a sodium dodecyl sulfate-polyacrylamide gel. The activity of the purified molecule (1.0 x 108 U/mg) was assayed and standardized as described previously (9) . Neutralizing polyclonal antibody to purified rHuTNF-a was raised in rabbits by standard procedures. The activity of the antiserum was 2.4 x 107 neutralizing units per ml (9) . A total of five separate experiments were conducted in which various concentrations of rHuTNF-a were administered intravenously to mice 24 h prior to lethal infection with Listeria Incubation of rHuTNF-ac with neutralizing polyclonal antibody for 30 min at 37°C immediately prior to its administration to mice abolished the protective effect (Table 3 ). It is important that all TNF preparations, sera, and reagents were free of endotoxin, as measured by the chromogenic enzyme assay (sensitivity, 0.1 ng/ml), and thus, the observed protection could not have been caused by contaminating LPS. A total of 0.5 ml was administered intraperitoneally prior to intravenous infection.
b The 50% effective dose was 0.033 mg/kg, and the 95% confidence interval was 0.019 to 0.57.
Additionally, since protection could be blocked by anti-TNF antibody, the effect of LPS acting through other possible pathways is unlikely.
'In our studies', the amount of TNF required to achieve protection against Listeria infection was higher than that measured in sera of mice that were injected with an amount of LPS necessary to attain a similar degree of protection. It is possible that endogenous TNF produced in response to LPS may, in actuality, reach substantially higher concentrations in discrete microenvironments within the host. Alternatively, given the short half-life of TNF in vivo (6) , relatively high levels of exogenous TNF may have to be injected in order to achieve an effective dose at the appropriate target. As is the case with LPS, there appears to be a window whereby TNF-induced protection is optimal. There was little or no protection observed when LPS or TNF was administered immediately prior to a Listeria challenge infection (data not shown). During the course of this study, Havell (7) and Nakane et al. (13) reported that treatment of L. monocytogenes-infected mice with antibody to recombinant murine TNF resulted in the enhanced growth of L. monocytogenes in vivo, with the subsequent conversion of a sublethal infection into a lethal one. While TNF could not be detected during the course of sublethal infection, those studies suggested a role' for TNF in the host defense to infection. Our results provide direct evidence that TNF plays an important role in host defense to listeriosis in mice and suggest that TNF may be a key mediator of some of the beneficial effects associated with LPS.
